新辅助免疫疗法加化学疗法与新辅助化学辐射疗法对食道状细胞癌患者的比较:一种倾向性得分匹配研究
Junfeng Zhao1,2, Shaoyu Hao3,4, Jing Tian5
1Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong, People's Republic of China.
Journal of inflammation research
|August 14, 2023
概括
与新辅助免疫疗法与化疗 (NICT) 相比,新辅助化学放射疗法 (NCRT) 对局部发达的食道状细胞癌显示出优异的病理反应和生存结果. 这两种治疗方法在本研究中都显示出相似的安全性.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 局部发达的食道状细胞癌 (ESCC) 需要有效的新辅助治疗策略.
- 将新辅助免疫疗法与化疗 (NICT) 和新辅助化学放射疗法 (NCRT) 相比较,对于优化患者的治疗结果至关重要.
研究的目的:
- 为了比较NICT与NCRT的疗效和安全性,然后在可切除,局部发达ESCC的患者中进行激进食道切除.
主要方法:
- 用NICT或NCRT和食道切除术治疗局部发达ESCC的患者的回顾性分析.
- 倾向性得分匹配 (PSM) 在1:2的比例,以平衡患者的特征.
- 评估瘤回归,病态完全缓解 (pCR),术后并发症,无病生存期 (DFS) 和整体生存期 (OS).
主要成果:
- 与NICT组相比,NCRT组的瘤回归度0级和pCR率显著更高 (分别为57.3%与32.7%和48.2%与29.1%).
- 与NICT组相比,NCRT组的12个月DFS和OS率明显更好 (分别为94.3%与81.8%和100.0%与95.4%).
- 在NCRT和NICT组之间,术后并发症的发生率相似 (P=0.082).
结论:
- 与NICT相比,NCRT为本地先进的ESCC提供了优越的病理反应和预后.
- 在这个患者队列中,NCRT和NICT的安全性表现相似.
- 手术后的PCR与局部发达ESCC患者的DFS改善有关.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
428
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
243
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
199
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
199
